Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management

Bryan Oronsky, Scott Caroen, Arnold Oronsky, Vaughn E. Dobalian, Neil Oronsky, Michelle Lybeck, Tony R. Reid, Corey A. Carter

Research output: Contribution to journalArticle


Platinum chemotherapy, particularly cisplatin, is commonly associated with electrolyte imbalances, including hypomagnesemia, hypokalemia, hypophosphatemia, hypocalcemia and hyponatremia. The corpus of literature on these dyselectrolytemias is large; the objective of this review is to synthesize the literature and summarize the mechanisms responsible for these particular electrolyte disturbances in the context of platinum-based treatment as well as to present the clinical manifestations and current management strategies for oncologists and primary care physicians, since the latter are increasingly called on to provide care for cancer patients with medical comorbidities. Correct diagnosis and effective treatment are essential to improved patient outcomes.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalCancer Chemotherapy and Pharmacology
StateAccepted/In press - Jul 20 2017
Externally publishedYes



  • Chemotherapy
  • Cisplatin
  • Electrolyte
  • Platinum
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Oronsky, B., Caroen, S., Oronsky, A., Dobalian, V. E., Oronsky, N., Lybeck, M., Reid, T. R., & Carter, C. A. (Accepted/In press). Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemotherapy and Pharmacology, 1-13. https://doi.org/10.1007/s00280-017-3392-8